Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting of hedgehog signaling.

Hegde GV, Nordgren TM, Munger CM, Mittal AK, Bierman PJ, Weisenburger DD, Vose JM, Sharp JG, Joshi SS.

Int J Cancer. 2012 Dec 15;131(12):2951-60. doi: 10.1002/ijc.27602. Epub 2012 May 21.

2.

Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.

Munger CM, Hegde GV, Weisenburger DD, Vose JM, Joshi SS.

Cancer Immunol Immunother. 2012 Oct;61(10):1819-32. Epub 2012 Mar 23.

PMID:
22441656
3.

Targeting of sonic hedgehog-GLI signaling: a potential strategy to improve therapy for mantle cell lymphoma.

Hegde GV, Munger CM, Emanuel K, Joshi AD, Greiner TC, Weisenburger DD, Vose JM, Joshi SS.

Mol Cancer Ther. 2008 Jun;7(6):1450-60. doi: 10.1158/1535-7163.MCT-07-2118. Epub 2008 Jun 4.

4.

Immunotherapy of human neuroblastoma using umbilical cord blood-derived effector cells.

Joshi AD, Clark EM, Wang P, Munger CM, Hegde GV, Sanderson S, Dave HP, Joshi SS.

J Neuroimmune Pharmacol. 2007 Jun;2(2):202-12. Epub 2006 Oct 10.

PMID:
18040845
5.

Dendritic cell-based therapy for mantle cell lymphoma.

Munger CM, Vose JM, Joshi SS.

Int J Oncol. 2006 Jun;28(6):1337-43.

PMID:
16685434
6.

Cytotoxicity of cord blood derived Her2/neu-specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo.

Wang P, Munger CM, Joshi AD, Pirruccello SJ, Joshi SS.

Breast Cancer Res Treat. 2004 Jan;83(1):15-23.

PMID:
14997051

Supplemental Content

Loading ...
Support Center